This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist in case of:
Abstract: Psoriasis is a common and difficult condition to treat. Corticosteroids and other agents are often used. Zinc pyrithione has been used for other related conditions. This study compares the use of combined micronized clobetasol propionate and zinc pyrithione (DermaZinc™ prescription strength) together VS control cream and generic clobetasol propionate alone. The one month study was double-blind controlled with treatments applied on either side of the body in a randomized fashion. There were 36 patients enrolled in the study. Of those, one was disqualified due to possible improper usage of the two test products DermaZinc™ Spray compounded with 50mg micronized Clobetasol Propionate VS generic Clobetasol Propionate, and three were disqualified due to substantial lapse of time between appointments. The psoriasis was examined for the following parameters: erythema, scaling, and thickness. The results demonstrate that the DermaZinc™ Spray compounded with 50mg micronized Clobetasol Propionate was significantly more effective than the generic clobetasol propionate alone for each parameter. In addition, the DermaZinc™ Spray compounded with 50mg micronized Clobetasol Propionate cleared lesions faster compared to generic Clobetasol Propionate. We conclude that there is a synergistic effect of using corticosteroids with zinc pyrithione in the treatment of psoriasis.
In an additional randomized study of subjects 12 years of age and older with mild to moderate plaque-type psoriasis, 253 subjects were treated with Olux-E (clobetasol propionate foam) Foam and 123 subjects were treated with Vehicle Foam. Subjects were treated twice daily for two weeks. At the end of treatment, 41 of 253 subjects (16%) treated with Olux-E (clobetasol propionate foam) Foam compared with 5 of 123 subjects (4%) treated with Vehicle Foam achieved treatment success. Treatment success was defined by an Investigator's Static Global Assessment (ISGA) score of clear (0) or almost clear (1) with at least 2 grades improvement from baseline, scores of none or faint/minimal (0 or 1) for erythema and scaling , and a score of none (0) for plaque thickness.